

The Liver Meeting® 2026
Abstract Categories and Descriptors

- **Acute Liver Failure and Artificial Liver Support**
 - Acute Liver Failure and Artificial Liver Support
- **Acute on Chronic Liver Failure**
 - Acute on Chronic Liver Failure
- **Advanced Practice Providers (NP, PA, RN, PharmD, etc.)**
 - Behavioral and Quality Issues
 - Practice Issues
- **Alcohol-Associated Liver Diseases: Clinical and Experimental**
 - Alcohol-Associated Liver Diseases: Clinical and Experimental
- **Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis**
 - Cholangiocyte Biology
 - Experimental Cholestasis
 - Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts
- **Cell and Molecular Biology**
 - Cell Structure and Function
- **Genomics and Precision Medicine**
 - Genomics and Precision Medicine
- **Gut Liver Axis and Microbiome**
 - Gut Liver Axis and Microbiome
- **Health Disparities/Health Equity Research**
 - Social Determinants of Health
 - Special Populations

- **Health Services and Public Health Research**
 - Cost-Effectiveness and Economics of Care
 - Health Care Delivery/Access/Quality

- **Hepatitis - Other Infections**
 - Hepatitis – Other Infections

- **Hepatitis B**
 - Diagnostics and Biomarkers – Hep B
 - Epidemiology, Prevention, Natural History – Hep B
 - Therapeutics: Approved Agents – Hep B
 - Therapeutics: New Agents – Hep B
 - Virology, Pathogenesis, and Immunology – Hep B

- **Hepatitis C**
 - Diagnostics and Biomarkers – Hep C
 - Epidemiology, Prevention, Natural History
 - Therapeutics: Approved and New Agents
 - Virology, Pathogenesis, and Immunology

- **Hepatobiliary Neoplasia**
 - Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma
 - Diagnostics and Liver Imaging
 - Experimental Hepatocarcinogenesis

- **Hepatotoxicity**
 - Drug Metabolism, Toxicity, and Therapeutics
 - Pathogenesis and Mechanisms
 - Predictors of Drug Toxicity

- **Human Cholestatic and Autoimmune Liver Diseases**
 - Autoimmune Liver Disease
 - PBC/PSC and Other Cholestatic Disease

- **Inflammation and Immunobiology**
 - Adaptive Immunity
 - Animal Models
 - Innate Immunity
 - Mechanisms of Injury

- **Liver Fibrogenesis and Non-Parenchymal Cell Biology**
 - Basic Fibrosis Research and Stellate Cell Biology
 - Clinical and Translational Fibrosis Research
 - Imaging and Noninvasive Markers of Liver Disease
 - Kupffer Cell Biology

- **Liver Transplantation and Liver Surgery**
 - Cellular Immunobiology, Preservation, and Cell Transplantation
 - Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
 - Immunosuppression, Outcomes, and Complications
 - Prevention and Treatment of Recurrent Disease

- **MASLD and MASH**
 - Diagnostics and Biomarkers – MASH
 - Epidemiology and Natural History, Prevention, and Outcomes
 - Experimental: Basic
 - Experimental: Clinical
 - Therapeutics: Approved/available agents
 - Therapeutics: New Agents
 - Treatment: Non-pharmacologic

- **Metabolic and Genetic Disease**
 - Hemochromatosis, Wilson Disease, and α -1 Antitrypsin Deficiency



- **Pediatric Hepatology**
 - Biliary Atresia and Neonatal Cholestasis
 - Metabolic and Genetic Diseases
 - Pediatric Liver Disease – Basic Science
 - Pediatric Liver Transplantation
 - Viral and Autoimmune Liver Disease
 - Portal Hypertension and Other Complications of Cirrhosis
 - Ascites, Renal Dysfunction, and Hepatorenal Syndrome

- **Portal Hypertension and Other Complications of Cirrhosis**
 - Encephalopathy, Infections, and Other Complications
 - Experimental
 - Varices and Bleeding

- **Vascular Liver Disease, Hemostasis, and Thrombosis**
 - Hemostasis and Thrombosis
 - Liver Sinusoidal Endothelial Cells
 - Vascular Liver Disease